The Global Fund Board has approved an extension of an existing malaria grant to Nigeria as well as a new one-year grant with a new principal recipient (PR) – all at no extra cost. The extension and the new grant will be financed by reinvesting savings identified in Nigeria’s current malaria grants. This will allow Nigeria to maintain essential malaria services to the end of 2017.
On 20 March 2017, Zimbabwe submitted a TB/HIV funding request to the Global Fund for $628.9 million. This includes an allocation request for $431.9 million and a prioritized above allocation request (PAAR) of $197 million. A separate funding request for malaria was submitted on the same day for $51.7 million.
For the first time, gender equality is included as a top-line strategic objective in the Global Fund’s Strategy (2017-2022). HIV prevention among adolescent girls and young women (AGYW) in sub-Saharan Africa will be a strong focus for the Global Fund in the coming funding cycle (2017-2019).
Catalytic investments: $800 million for matching funds, multi-country approaches, and strategic initiatives
The Global Fund Board has approved $800 million to be set aside for catalytic investments over the 2017-2019 grant cycle. These investments are intended to catalyze country allocations to ensure they deliver results against the aims of 2017-2022 Global Fund Strategy.